Wednesday, December 05, 2012
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
The New Neonatal Care Center at Soroka Medical Center
The New Neonatal Care Center at Soroka Medical Center 1 2 The New Neonatal Care Center at Soroka Medical Center The new Neonatal Care Center will serve all newborns in the Negev and provide full protection against missile attacks in accordance with the standards of the Home Front Command of the Israel Defense Forces. Soroka Medical Center: An Overview With 1,100 beds, Soroka Medical Center is among Israel’s largest and most advanced hospitals, and the country’s busiest. Soroka is the only major medical center in the entire Negev, serving a population of more than one million inhabitants, including 400,000 children, in a region that accounts for 60% of the country’s total land area. Soroka serves as the teaching hospital of both the Medical School of Ben-Gurion University, whose Faculty of Health Sciences is located on the hospital campus, and its Medical School for International Health. On par with leading international institutions, Soroka specializes in areas that include, for example, early detection and treatment of breast cancer using minimally invasive procedures; non-invasive removal of malignant tumors; trauma rehabilitation of children and adolescents; pediatric infectious diseases; and much more. Each year, excellent care is provided to more than 750,000 people at outpatient and clinic visits; 235,000 patients visit our Emergency Medicine Department (the busiest in the country); 80,000 inpatients fill our beds; over33 ,000 patients undergo surgery, and more than 17,000 babies are born. Soroka’s neonatal and pediatric departments provide family-centered intensive care with world-class survival rates. Soroka’s Trauma Unit is the largest and busiest in Israel, always on call, 24 hours a day, 365 days a year. -
0201 Haplotype on the Risk for Multiple Sclerosis in Diverse Arab Populations in Israel
Genes and Immunity (2010) 11, 423–431 & 2010 Macmillan Publishers Limited All rights reserved 1466-4879/10 www.nature.com/gene ORIGINAL ARTICLE Opposing effects of the HLA-DRB1*0301-DQB1*0201 haplotype on the risk for multiple sclerosis in diverse Arab populations in Israel G Benedek1,6, T Paperna2,6, N Avidan2, I Lejbkowicz2, JR Oksenberg3, J Wang3, C Brautbar1,4, S Israel4 and A Miller2,5, for the Israeli MS Genetics group7 1The Lautenberg Center for Immunology, Hebrew University Hadassah Medical School, Jerusalem, Israel; 2Faculty of Medicine, Rappaport Research Institute, Technion–Israel Institute of Technology, Haifa, Israel; 3Department of Neurology, University of California, San Francisco, CA, USA; 4Tissue Typing and Immunogenetics Unit, Hadassah Medical Center, Jerusalem, Israel and 5Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel Different multiple sclerosis (MS) prevalence rates were reported for Muslim and Christian Arabs in Israel. In this study, we evaluated whether associations of human leukocyte antigen (HLA) genes with MS may contribute to this prevalence difference. DNA samples from Israeli Arab MS patients (n ¼ 109) and controls (n ¼ 132) were typed for HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and -DQB1) genes. Global comparisons of HLA allele frequencies revealed significant differences between Christians and Muslims; therefore, case–control analyses were stratified by religious affiliation. Disease characteristics of Muslim and Christian Arab MS patients were similar to those reported for European populations. Opposing association signals with MS were observed for alleles composing the DRB1*0301-DQB1*0201 haplotype: positive association of the HLA- DRB1*0301 allele in Muslims (PBonferroni ¼ 0.004, odds ratio (OR) ¼ 3.07), and negative association in Christian Arabs (PBonferroni ¼ 0.01, OR ¼ 0.12), with similar results obtained for HLA-DQB1*0201. -
Curriculum Vitae Shay Schneider, M.D
April, 2020 Curriculum Vitae Shay Schneider, M.D Name: Shay Schneider Date of birth: December 23, 1979 Place of birth: Tel Aviv, Israel Family status: Married +2 Telephone: +972-54-7685189 E mail: [email protected] CLINICAL EXPERIENCE Sep 2018-present: Senior staff member Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Sep 2018-Sep 2020: Clinical Fellow (Rhinology and skull base surgery), A.R.M, Center of Otolaryngology/ Head and Neck Surgery, Assuta Medical Center, Tel Aviv, Israel. Sep 2012-Sep 2018: Resident: Otolaryngology department, Soroka University Medical Center, Beer Sheva, Israel. Jan 2011 - Jan 2012: Rotating internship year: Training physician in internal medicine, general surgery, anesthesia and pediatrics units, Barzilai Medical Center in Ashkelon, Israel. Jun 2009 - Aug 2009: Clinical rotation in Otolaryngology, Shaare Zedek Medical Center in Jerusalem, Israel. ACADEMIC DEGREES 2016- present: Instructor, Faculty of Health Sciences, Ben Gurion University, Beer Sheva, Israel. 2004-2010: MD degree, Third Medical Faculty, Charles University in Prague (English program), Czech Republic. POST ACADEMIC COURSES Jan 2020: Baloon sinuplasty and Eustachian tuboplasty, Madeira, Portugal. Aug-Sep 2018: Observership, University of Texas MD Anderson Cancer Center, Houston, Texas. United States 2013-2018: School of Continuing Studies, Otolaryngology program, The Sackler Faculty of Medicine, Tel Aviv University, Israel. June 2017: Rhinoplasty course, Ziv Medical Center, Israel Feb 2017: 4th Annual OSAS International Surgery Course, Florida Hospital Nicholson Center & Florida Hospital Celebration Health, Celebration, United States. Feb 2017: Trans- oral laser surgery (TLS) course, Kaplan Medical Center. Sep 2016: Head and neck dissection course, Tel Aviv University. Oct 2014: Sedation course, Sheba Medical Center, Tel Aviv. -
Antibiotic Treatment for Invasive Listeriosis and Patient
Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality. -
The Peres Center for Peace, Tel-Aviv April 12Th, 2019
April 12th, 2019 The Peres Center for Peace, Tel-Aviv BREAST CANCER INNOVATIONS The Israeli Society for Clinical Oncology and Radiation Therapy and Roche are Pleased to Invite You to an Enriching and Educating Meeting with our Distinguished Guest Speaker: Prof. Charles E. Geyer Please Send the Attached Registration Form to A.M Knasim No Later than April 1st 2019 E-mail: [email protected] Tel: 03-6081520 Fax: 03-6081522 Prof. Charles E. Geyer Friday, 12th April 2019 • Professor of Medicine 08:00-09:00 Welcome Reception • Harrigan, Haw, Luck Families Chair in Cancer Research 09:00-09:10 Opening Remarks • Virginia Commonwealth University, Massey Dr. Noa Efrat Ben-Baruch Cancer Center Head, Israeli Breast Cancer Group • Associate Director of Clinical Research Head, Department of Oncology Kaplan Medical Center Charles E. Geyer, Jr. is Professor of Medicine and the Harrigan, Haw, Luck Families Chair in Cancer Research at Virginia Commonwealth University Massey Chairmen: Dr. Georgeta Fried Cancer Center, an NCI-designated Cancer Center. He serves as Associate Director Head Breast Cancer Unit of Clinical Research for the Massey Cancer Center with oversight responsibility Rambam Medical Center for all cancer-related clinical research activities within the Center. Prof. Geyer Dr. Margarita Tokar has devoted most of his academic career on the design and conduct of multi- institutional, phase III clinical trials in breast cancer with a particular focus on Senior Oncologist the development of HER2 targeted therapies. He has served in several leadership Soroka University Medical Center positions for multi-institution research initiatives. These include vice-chair of the 09:10-09:30 Personalized Nanothechnologies in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Committee Management of Breast Cancer from 1999 until 2007, Associate Director of Medical Affairs from 2002 to 2006 and Director of Medical Affairs for NSABP from 2006 to 2011. -
APF Newsletter, Winter 2006 – 2007
Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs. -
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted -
Antibiotic Treatment for Invasive Nonpregnancy-Associated Listeriosis and Mortality: a Retrospective Cohort Study
European Journal of Clinical Microbiology & Infectious Diseases (2019) 38:2243–2251 https://doi.org/10.1007/s10096-019-03666-0 ORIGINAL ARTICLE Antibiotic treatment for invasive nonpregnancy-associated listeriosis and mortality: a retrospective cohort study Yaakov Dickstein1 & Yonatan Oster2 & Orit Shimon3 & Lior Nesher4 & Dafna Yahav3,5 & Yonit Wiener-Well6 & Regev Cohen7,8 & Ronen Ben-Ami3,9 & Miriam Weinberger3,10 & Galia Rahav3,11 & Yasmin Maor3,12 & Michal Chowers3,13 & Ran Nir-Paz2 & Mical Paul1,8 Received: 22 May 2019 /Accepted: 30 July 2019 /Published online: 10 August 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Little evidence exists addressing the clinical value of adding gentamicin to ampicillin for invasive listeriosis. A multicenter retrospective observational study of nonpregnant adult patients with invasive listeriosis (primary bacteremia, central nervous system (CNS) disease, and others) in 11 hospitals in Israel between the years 2008 and 2014 was conducted. We evaluated the effect of penicillin-based monotherapy compared with early combination therapy with gentamicin, defined as treatment started within 48 h of culture results and continued for a minimum of 7 days. Patients who died within 48 h of the index culture were excluded. The primary outcome was 30-day all-cause mortality. A total of 190 patients with invasive listeriosis were included. Fifty-nine (30.6%) patients were treated with early combination therapy, 90 (46.6%) received monotherapy, and 44 (22.8%) received other treatments. Overall 30-day mortality was 20.5% (39/190). Factors associated with mortality included lower baseline functional status, congestive heart failure, and higher sequential organ failure assessment score. -
Comprehensive Cancer Center This Is Untenable
CompSorrehensokaive Cancer Center SOROKA MEDICAL CENTER Today’s Challenge Today’s FACTS Tel Aviv 60 Percent of Israel’s landmass 1,000,000 Total Population Jerusalem 300 Percent increase of cancer cases in the Negev over past 20 years due in large part to increase in population Last year at Soroka Medical Center: Gaza Soroka Hospitalizations in the Oncology and Medical 1,645 Hematology Wards Center Beer Patients cared for in the Ambulatory Sheva 15,923 Oncology and Hematology Units 24,451 Patients cared for in the Oncology and The Negev Hematology Clinics 17,987 Radiation therapy treatments 40,243 Chemotherapy treatments 100,249 Total number of cancer-related hospital visits miles a person in the southern tip of the Negev must 221 currently travel to reach a comprehensive cancer center This is untenable. 3 There is NO comprehensive cancer center in the Negev. Coping with cancer is difficult enough under the best of circumstances. There are the elements of fear and doubt, questions about how to handle it with the family and how to get the most effective treatment. The challenge is greatly compounded when the closest comprehensive cancer center is hours away and transportation is limited. Many residents in the Negev are impoverished and from traditional societies. If care is not easily accessible they simply will not get treatment. Chemotherapy treatment today 4 Growing Needs and Changing Winds Components for cancer treatment that do exist arose out of the Negev’s growing need for cancer care and they are scattered and overcrowded. Even more pressing is the fact that the Oncology Department is housed in Soroka Medical Center’s emergency underground hospital. -
Neuro-Ophthalmology in Israel
Worldwide Neuro-Opthalmology Section Editor: Kathleen B. Digre, MD Neuro-Ophthalmology in Israel Ruth Huna-Baron, MD, Eitan Zvi Rath, MD FIG. 1. Pioneers of neuro-ophthalmology in Israel. euro-ophthalmology was introduced in Israel during challenge of the rapid development of new and expensive N the late 1970s by Riri Manor, Yochanan Goldhammer, diagnostic and therapeutic modalities, a committee of the and Isaac Gutman (Fig. 1). They trained with from William Ministry of Health each year announces new technologies Hoyt, Lawton Smith, and Myles Behrens, respectively. These and therapies to be included in basic health coverage. There pioneers trained many local ophthalmologists, neurologists, are 18 magnetic resonance imaging devices in Israel and 5 and neuro-ophthalmologists in Israel, and their efforts resulted interventional neurovascular units, and most medical in 21 neuro-ophthalmologists currently serving a population centers in the country have a neuro-ophthalmology service of 8 million. Many Israeli neuro-ophthalmologists did fellow- (Table 1). Much like in the United States, referrals come ships in the United States with a variety of other mentors, from neurologists, ophthalmologists, neurosurgeons inter- including Ronald Burde, Joel Glaser and Norman Schatz, ventional neuroradiologists, and endocrinologists. Mark Kupersmith, Byron Lam, Neil Miller, Barry Scarf, In 1997, the Israeli Neuro-Ophthalmology Society was and Jonathan Trobe. founded by Ririo Manor as a subspecialty section of the In Israel, each citizen is entitled to health care services Israeli Ophthalmology Society. Two annual meetings are under the National Health Insurance Law. To meet the organized by the society, of which one hosts a leading TABLE 1. -
The Israel Multiple Sclerosis Society the IMSS Publishes in 4 Languages & All Provides Services to Persons with MS Services Are Provided in 4 Languages
The Israel +972 - 3 - 53 77 002 Multiple Sclerosis Society [email protected] www.mssociety.org.il The Israel Multiple Sclerosis society The IMSS publishes in 4 languages & All provides services to persons with MS services are provided in 4 languages. belonging to the diverse sectors of The Society adapts its activities to population that make up the State of meet the various requirements and Israel: Hebrew, Arab, Russian, English customs of the various sectors & speaking persons. different minorities. The Israel MS society activities MS 27 multidisciplinary Support Peer adult groups counseling enrichment group 01 MS site resort 27 Support groups facilitated by Hotline professional psychologists & social 16 01 Society 15 workers in Hebrew, Arabic, Russian library 02 The support groups operate throughout the country. The groups meet once every two, three or four weeks 14 & some 30- 35 patients & family members participate in 03 Community each meeting. These meetings provide an opportunity Book listing social to relieve tensions, share problems & get advice & the rights of13 worker encouragement. MS patients 04 Russian language 8 12 social worker 02 Seminars & conferences 05 Peer counseling group Yearly in which patients who have had special training provide 11 telephone counseling to other patients. The counselors Grants 20 Social meet once a month for training. & loans 06 Work fund 10 07 students Legal 09 Data Coordinator 08 in Arabic 03 advice Yearly MS Hotline patients Yearly Excursions Summer run by a coordinator & specially trained operators, who camp handle incoming & outgoing calls to/from patients & & vacations members of their families. 04 Community social worker individual & community information & counseling, help 09 with referrals to government agencies, home visits. -
Israeli Cardio-Oncology Society Virtual Meeting Preliminary Program
January 13-14, 2021 | Virtual Conference TOWARDS A COMPREHENSIVE CARDIAC-CANCER CARE Take this unique opportunity to join the ISCO 2021 conference and to effectively reach hundreds of cardiologists, oncologists and hemato-oncologists. Join us and present your research and technology to this influential and knowledgeable audience, and to have full access to all networking benefits. Conference secretariat - Dirigo Events & Conferences 3 Menorat Hamaor st. Tel-Aviv, Israel For more information, please contact: Tel: 03-7775485 | Email: [email protected] Yael Ziv Project Manager – Industry Liaison, Dirigo | Mobile: +972-54-5599821 | Email: [email protected] ISRAELI CARDIO-ONCOLOGY SOCIETY VIRTUAL MEETING PRELIMINARY PROGRAM Platinum Sponsorship Gold Sponsorship Silver Sponsorship January 13, 2021 15:45-16:00 Opening Session 15:45-15:47 Zaza Iakobishvili, Founder and Chair of the Meeting, Cardiology 15:47-15:49 Dan Gilon, Chair of the Meeting, Cardiology 15:49-15:51 David Sarid, Chair of the Meeting, Oncology 15:51-15:53 Martin Ellis, Chair of the Meeting, Hematology 15:53-15:55 Alex Lyon, ESC Cardio-Oncology Council 15:55-15:57 Bonnie Ky, JACC Cardio-Oncology 16:00-17:00 Plenary Session Chairs: Giorgio Minnotti, Faculty of Medicine and Surgery, Campus Bio-Medico University of Rome, Italy Alexander Battler, Chairman, Advisory Council on Cardiovascular Disease Management and Prevention, Ministry of Health, Israel 16:00-16:20 How to establish Cardio-Oncology collaboration Susan F. Dent, Associate Director of Breast Cancer Clinical Research, Co-Director Duke Cardio-Oncology Program, Durham, NC, USA 16:20-16:40 Guidelines in Cardio-Oncology: Gaps and Opportunities José Luis Zamorano, University Hospital Ramon Y Cajal, Madrid, Spain 16:40-17:00 Panel discussion: Future of Cardio-Oncology Richard H.